Cancer Supportive Care Products Market to 2016 - Market is Expected to Decline after 2014 Due to Generic Erosion and Entry of Biosimilars - GBI Research Reports

Cancer Supportive Care Products Market to 2016 - Market is Expected to Decline after 2014 Due to Generic Erosion and Entry of Biosimilars

Cancer Supportive Care Products Market to 2016 - Market is Expected to Decline after 2014 Due to Generic Erosion and Entry of Biosimilars - GBI Research Reports
Cancer Supportive Care Products Market to 2016 - Market is Expected to Decline after 2014 Due to Generic Erosion and Entry of Biosimilars
Published Apr 01, 2011
137 pages — Published Apr 01, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest research, Cancer Supportive Care Products Market to 2016 Market is Expected to Decline after 2014 Due to Generic Erosion and Entry of Biosimilars, which provides insights into the cancer supportive care products market and forecasts until 2016. The report provides an in-depth analysis of the six major cancer supportive care products indications, which are oral mucositis and dry mouth, chemotherapy-induced nausea and vomiting, cancer pain, chemotherapy-induced anemia, chemotherapy-induced neutropenia and bone metastases. The report also looks into the major unmet needs in the cancer supportive care products market and the major classes of drugs that treat the indications covered in the sector. The report also analyzes the key drivers and restraints that are expected to impact each of the indications in the global cancer supportive care products market. The report also delves into the cancer supportive care products market in the top seven countries in the world, which includes the US, the UK, Germany, France, Italy, Spain and Japan. In addition, the report also includes insights into the R&D (Research & Development) pipeline for the six cancer supportive care indications. In addition, the report also looks into the major M&A (Mergers & Acquisitions) and licensing deals that have taken place between 2008 and 2010 in the global cancer supportive care products market space.

Scope

The scope of this report includes -
- Data and analysis on the cancer supportive care products market.
- Annualized market data for the cancer supportive care products market from 2001 to 2009, with forecasts to 2016.
- Market data on the therapeutic landscape which covers oral mucositis and dry mouth, chemotherapy-induced nausea and vomiting, cancer pain, chemotherapy-induced anemia, chemotherapy-induced neutropenia and bone metastases, including market size, market share, annual cost of therapy, treatment usage patterns such as prevalence population and prescription population.
- Key drivers and restraints that have had a significant impact on the market and on each indication.
- The geographic landscape that covers the US, the top five countries of Europe (the UK, France, Germany, Spain and Italy) and Japan.
- The competitive landscape of the cancer supportive care products market which includes companies such as Amgen, Johnson & Johnson, Roche, Novartis and Pfizer
- Key M&A activities and Licensing Agreements that took place from 2008 to 2010 in the cancer supportive care products market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading countries and therapeutic segments poised for strong growth.
- Devise a more tailored country strategy through the understanding of key drivers and barriers of each regions pharmaceutical market.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

  
Source:
Document ID
GBIHC082MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents48
  List of Tables72
  List of Figures93
Cancer Supportive Care Products Market: Introduction121
  GBI Research Report Guidance121
Cancer Supportive Care Products Market: Market Overview1315
  Revenue131
  Average Annual Cost of Therapy141
  Therapeutic Segmentation151
  Geographic Segmentation164
  Generic Share in the Cancer Supportive Care Products Market201
  Drivers and Restraints of Cancer Supportive Care Products Market211
    Drivers211
      Growth in the Markets of Bone Metastases, Cancer Pain and Oral Mucositis and Dry Mouth211
      Increase in Cancer Prevalence211
      High Unmet Need, Specifically With Respect to Drug Efficacy and Safety211
    Restraints221
      Patent Expiry of Leading Drugs in Major Cancer Supportive Care Products Markets221
      Weak Pipeline with Very Few Promising Molecules221
      Increased Uptake of Combination Therapies for Cancer that Reduces the Adverse Events Related to Chemotherapy221
  Unmet Needs231
    Efficacy231
    Safety231
    Price231
  Major Drug Classes241
    Anti-infectives (Oral Mucositis)241
    Anti-emetics (CINV)241
    Bisphosphonates (Bone Metastases)251
    Erythropoietin Stimulating Agents (CIA)251
    Granulocyte Colony Stimulating Factors (CINP)261
    Opioid Analgesics (Cancer Pain and Bone Metastases)261
    NSAIDs (Cancer Pain and Bone Metastases)261
    Monoclonal Antibodies (Bone Metastases)271
Cancer Supportive Care Products Market: Therapeutic Landscape2861
  Oral Mucositis and Dry Mouth Market281
    Introduction281
    Revenue291
    Annual Cost of Therapy301
    Treatment Usage Patterns311
      Prevalence Population321
      Prescription Population331
    Drivers for the Oral Mucositis and Dry Mouth Market331
      High Unmet Need331
    Restraints for the Oral Mucositis and Dry Mouth Market341
      Patent Expiries of Kepivance341
      Availability of Alternate Non-Pharmacological Treatment Options341
    Geographical Segmentation344
  Chemotherapy Induced Nausea and Vomiting Market381
    Introduction382
    Revenue401
    Annual Cost of Therapy411
    Treatment Usage Patterns421
      Prevalence Population431
      Prescription Population441
    Drivers for the Chemotherapy Induced Nausea and Vomiting Market441
      Increase Uptake of Novel Anti-Emetics Such As Emend441
      Increase in Cancer Prevalence441
    Restraints for the Chemotherapy Induced Nausea and Vomiting Market451
      Patent Expiry of Leading Anti-Emetics Such As Aloxi, Emend and Anzemet451
      Better Chemotherapy Drugs with Low or Minimal Emetic Risk451
    Geographical Landscape463
  Cancer Pain Market491
    Introduction491
    Revenue491
    Annual Cost of Therapy501
    Treatment Usage Patterns511
      Diseased Population521
      Treatment Seeking Population531
      Diagnosed Population541
      Prescription Population551
    Drivers for the Cancer Pain Market561
      Increasing Treatment Seeking, Diagnosis and Prescription Rate Will Drive the Market561
      New Modes of Delivery Will Help in Better Management of the Pain for a Longer Duration561
    Restraints for the Cancer Pain Market561
      Concerns over the Risks of Addiction Related to Drug Therapy Will Affect the Prescription Rate561
    Geographical Landscape573
  Chemotherapy Induced Anemia Market601
    Introduction601
    Revenue602
    Annual Cost of Therapy621
    Treatment Usage Patterns631
      Prevalence Population641
      Prescription Population651
    Drivers for the Chemotherapy Induced Anemia Market661
      Greater Efficacy of Combination Therapies (Erythropoietins and Iron IVs)661
      High Unmet Need in Terms of Drug Safety661
    Restraints for the Chemotherapy Induced Anemia Market661
      Restrictions on the Use of Erythropoietins661
      Declining Incidence of CIA in the Chemotherapy Patient Population661
      Entry of Biosimilars661
    Geographical Landscape673
  Chemotherapy Induced Neutropenia Market701
    Introduction701
    Revenue711
    Annual Cost of Therapy721
    Treatment Usage Patterns731
      Prevalence Population741
      Prescription Population751
    Drivers for the Chemotherapy Induced Neutropenia Market761
      Higher Uptake of G-CSFs761
      Increased Affordability Due to Entry of Biosimilars761
    Restraints for the Chemotherapy Induced Neutropenia Market761
      Patent Expiries of Leading G-CSFs761
      Weak Pipeline761
    Geographical Landscape772
  Bone Metastases Market791
    Introduction791
    Revenue801
    Annual Cost of Therapy811
    Treatment Usage Patterns821
      Prevalence Population831
      Prescription Population841
    Drivers for the Bone Metastases Market851
      Increased Uptake of Monoclonal Antibodies such as Denosumab851
      Increasing Prevalence of Cancer and Resulting Population Suffering From Bone Metastases851
    Restraints for the Bone Metastases Market851
      Patent Expiry of Leading Bisphosphonates such as Zometa and Boniva851
    Geographical Landscape863
Cancer Supportive Care Products Market: Geographical Landscape8910
  The US891
    Revenue891
    Average Annual Cost of Therapy901
    Therapeutic Segmentation911
  Top Five Countries of Europe921
    Revenue921
    Average Annual Cost of Therapy931
    Therapeutic Segmentation941
    Geographic Segmentation951
  Japan961
    Revenue961
    Average Annual Cost of Therapy971
    Therapeutic Segmentation981
Cancer Supportive Care Products Market: Pipeline Analysis9914
  Introduction992
    Research and Development Pipeline Oral Mucositis and Dry Mouth1011
    Research and Development Pipeline Chemotherapy Induced Nausea and Vomiting1021
    Research and Development Pipeline Cancer Pain1031
    Research and Development Pipeline Chemotherapy Induced Anemia1041
    Research and Development Pipeline Chemotherapy Induced Neutropenia1051
    Research and Development Pipeline Bone Metastases1061
  Profiles of Promising Drugs in the Cancer Supportive Care Products Market1071
    Xgeva/Prolia (denosumab) Bone Metastases1071
      Product Description1071
      Mechanism of Action1071
      Clinical Study Details1071
    Alpharadin Bone Metastases1081
      Product Description1081
      Mechanism of Action1081
      Clinical Study Details1081
    MAXY-G34 Chemotherapy Induced Neutropenia1091
      Product Description1091
      Mechanism of Action1091
      Clinical Study Details1091
    Lactermin Oral Mucositis1091
      Product Description1091
      Mechanism of Action1101
      Clinical Study Details1101
    Xen2174 Cancer Pain1101
      Product Description1101
      Mechanism of Action1101
      Clinical Study Details1111
    Tectin Cancer Pain1111
      Product Description1111
      Mechanism of Action1111
      Clinical Study Details1111
    NasalFent Cancer Pain1121
      Introduction1121
      Mechanism of Action1121
      Clinical Study Details1121
Cancer Supportive Care Products Market: Competitive Landscape11311
  Market Share Analysis1131
  Competitive Profiling1141
    Amgen1141
      Business Description1141
      Products Portfolio1141
      Pipeline Portfolio1151
      SWOT Analysis1161
    Johnson &Johnson1161
      Business Description1161
      Products Portfolio1171
      Pipeline Portfolio1171
      SWOT Analysis1181
    F. Hoffmann-La Roche1181
      Business Description1181
      Products Portfolio1191
      Pipeline Portfolio1191
      SWOT Analysis1191
    Novartis1201
      Business Description1201
      Products Portfolio1201
      Pipeline Portfolio1211
      SWOT Analysis1211
    Pfizer1221
      Business Description1221
      Products Portfolio1221
      Pipeline Portfolio1231
      SWOT Analysis1231
Cancer Supportive Care Products Market: Deals Landscape1247
  M&A and Licensing Agreements1241
    Deals by Year1241
    Deals by Deal Type1251
    Deals by Indication1261
    Deals by Value ($m)1271
    Deals by Geography1281
    Major Acquisitions in the Cancer Supportive Care Products Market1281
      Amgen Acquires Dompe Biotec1281
    Major Licensing Agreements in the Cancer Supportive Care Products Market1291
      Nektar Therapeutics Enters Into Licensing Agreement with AstraZeneca1291
      Celgene Enters Into Co-Development Agreement with Acceleron Pharma1291
      Amgen Enters Into Co-Development Agreement with Takeda Pharmaceutical1301
      Algeta Signs Licensing Agreement with Bayer1301
      Amgen Enters Into License Agreement with Ortho-McNeil-Janssen1301
Cancer Supportive Care Products Market: Appendix1317
  Market Definitions1311
  Abbreviations1312
  Research Methodology1334
    Coverage1331
    Primary Research1341
    Forecasts1341
      Epidemiology-based Forecasting1342
    Expert Panel Validation1361
  Contact Us1371
  Disclaimer1371
  Sources1371

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Cancer Supportive Care Products Market to 2016 - Market is Expected to Decline after 2014 Due to Generic Erosion and Entry of Biosimilars" Apr 01, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Cancer-Supportive-Care-Products-Market-to-2016-Market-is-Expected-to-Decline-after-2014-Due-to-Generic-Erosion-and-Entry-of-Biosimilars-2115-187>
  
APA:
GBI Research Reports. (2011). Cancer Supportive Care Products Market to 2016 - Market is Expected to Decline after 2014 Due to Generic Erosion and Entry of Biosimilars Apr 01, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Cancer-Supportive-Care-Products-Market-to-2016-Market-is-Expected-to-Decline-after-2014-Due-to-Generic-Erosion-and-Entry-of-Biosimilars-2115-187>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.